Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response.

ABSTRACT:

Background

Approximately 15%-20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in treatment have been achieved after the introduction of trastuzumab and lapatinib, many patients do not benefit from these drugs. Therefore, in-depth understanding of the mechanisms behind the treatment responses is essential to find alternative therapeutic strategies.

Materials and methods

Thirteen HER2 positive breast cancer cell lines were screened with 22 commercially available compounds, mainly targeting proteins in the ErbB2-signaling pathway, and molecular mechanisms related to treatment sensitivity were sought. Cell viability was measured, and treatment

SUBMITTER: Jernstrom S 

PROVIDER: S-EPMC5367762 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature